NCT06740825View on ClinicalTrials.gov

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

December 9, 2024

Conditions
Healthy Subjects
Interventions
DRUG

Quizartinib

Single oral dose of 60 mg

DRUG

Rufinamide

Twice daily (BID) dose of 400 mg on Days 1 through 32

Trial Locations (1)

78217

WCT, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY